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OBJECTIVES The current study was designed to examine whether ubiquitin expression is higher in unstable
than in stable lesions of patients with acute coronary syndrome (ACS).
BACKGROUND The ubiquitin system has been identified as the nonlysosomal pathway of protein degradation;
it is involved in a number of biologic processes crucial to cell and tissue integrity and
therefore, might be potentially involved in the rupture of unstable coronary plaques.
METHODS We conducted an autopsy-based study of 25 consecutive patients with fatal ACS. Lesions of
both infarct-related and noninfarct-related segments from the same patients were examined
for the expression and localization of ubiquitin by use of immunohistochemistry and a
semiquantitative grading scale.
RESULTS Ubiquitin immunoreactivity was higher in infarct-related than in noninfarct-related lesions
(1.4  0.5 vs. 1.1  0.6, p  0.03). Compared with areas adjacent to the plaque (0.6  0.7),
ubiquitin immunoreactivity was higher in areas around the lipid core (2.5  0.8, p  0.001),
plaque shoulders (1.6  1.1, p  0.001), and fibrous cap regions (1.6  1.1, p  0.001).
Within the plaque area, co-localization of ubiquitin immunoreactivity with T cells and
macrophages was found. In areas adjacent to the plaque, ubiquitin immunoreactivity
co-localized with neointima cells and media smooth muscle cells.
CONCLUSIONS In patients with ACS, ubiquitin immunoreactivity is enhanced in unstable, infarct-related
lesions, predominantly in plaque regions of tissue degradation. Based on these findings, this
study suggests a role for the ubiquitin system in the destabilization and rupture of coronary
atherosclerotic plaques in humans. (J Am Coll Cardiol 2002;40:1919–27) © 2002 by the
American College of Cardiology Foundation
Atherosclerosis research has revealed molecular mediators
and mechanisms involved in the atherosclerotic process (1,2).
Notably, inflammation and matrix protein degradation have
been associated with the rupture of unstable coronary plaques,
resulting in acute coronary syndrome (ACS) (3–6).
The ubiquitin-mediated proteolytic pathway involves the
conjugation of multiple moieties of ubiquitin, a 76-amino-
acid polypeptide, to cellular proteins in a multienzymatic
process, targeting these proteins to degradation (7,8). As the
majority of cellular proteins are affected by this nonlysoso-
mal pathway of protein degradation, the ubiquitin system
has been identified as crucially involved in a variety of biologic
processes, maintaining cell and tissue integrity (7). Thus, it
may conceivably play a role in the process of coronary plaque
instability and rupture. The current study has been designed to
test whether ubiquitin expression is higher in unstable than in
stable lesions of patients with ACS.
METHODS
Study population. Approved by the Institutional Review
Board, the study included 25 consecutive patients with fatal
ACS, in which, acute or subacute myocardial infarction
(MI) was confirmed by autopsy at the Mayo Clinic Roch-
ester during 1995 and 1996 (9–11). In addition, five
patients with noncardiac death were included as a reference
group.
After gross evaluation, sections were taken from anterior,
lateral, and inferior regions of the left and right ventricles at
basal, middle, and inferior regions. Presence and age of MI
were determined according to previously published criteria
(12). Myocardial infarctions were designated as transmural
if they extended 50% of wall thickness, as subendocardial
if they extended 50% of wall thickness, and as mixed if a
combination of both was present.
At autopsy, coronary arteries were fixed in 10% neutral
buffered formalin. Subsequently they were embedded in
paraffin, sectioned at 5 m, and stained with hematoxylin-
eosin and Verhoeff-van Gieson (13).
Immunohistochemistry. As described in detail before
(14), after deparaffinization and rehydration, endogenous
peroxidase activity and nonspecific protein binding sites
were blocked by equimolar H2O2 methanol solution and 5%
goat, respectively. Anti-ubiquitin primary antibody (Sigma,
St. Louis, Missouri) was applied at a dilution of 1:100 at
4°C overnight. Biotinylated secondary antibody (rabbit IgG,
dilution 1:400, Dako, Carpinteria, California) was detected
by peroxidase-conjugated streptavidin (dilution 1:500,
Dako) and visualized by 3-amino-9-ethylcarbazole (Sigma).
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Tissue cell types were identified by use of anti-smooth
muscle alpha-actin (dilution 1:1500, Dako), anti-
macrophage KP 1 (dilution 1:200, Dako), and anti-T cell
CD 3 (dilution 1:200, Dako). Expression of p53 was
assessed by a monoclonal antibody (dilution 1:100, Cell
Signaling Technology, Inc., Beverly, Massachusetts). All
sections were counterstained with hematoxylin.
Terminal deoxynucleotidyl transferase end labeling
(TUNEL) assay. Cells undergoing apoptosis were identi-
fied by the (TdT) end labeling TUNEL technique using the
ApopTag In Situ Apoptosis Detection Kit from Intergen
(Intergen Company, Purchase, New York). Briefly, depar-
affinized and hydrated sections were digested with 20 g/ml
proteinase K for 11 min at room temperature (RT), fol-
lowed by rinsing and permeabilization of tissue by incuba-
tion with 0.05% triton 100 in 0.05% sodium citrate for
5 s. After rinsing, endogenous peroxidase activity was
quenched by incubation with 1.5% H2O2 at RT for 15 min.
Sections were successively incubated with equilibration
buffer (5 min at RT), terminal deoxynucleotidyl transferase
(TdT) enzyme (60 min at 37°C), stop/wash buffer (10 min
at RT), and protein block (Dako) (7 min at RT). After
incubation with anti-digoxygenin peroxidase at RT for
30 min and rinsing, slides were incubated with NovaRed
substrate for 2 min at RT and counterstained with hema-
toxylin. Female rodent mammary gland tissue, three to five
days after weaning, was used as a positive control, assuring
a rate of apoptotic cells of 1% to 2% (provided by Intergen
Company, Purchase, New York) (15). Omission of TdT
enzyme from the labeling procedure served as a negative
control (16).
Double-label immunohistochemistry. To further identify
cell types expressing ubiquitin immunoreactivity, double-
label immunostaining of specimens was performed using the
EnVision Doublestain Kit (Dako) with the specific anti-
bodies mentioned previously. In the first step, the ubiquitin
antibody was detected by a peroxidase-labeled secondary
antibody with 3,3-diaminobenzidine tetrahydrochloride as
chromogen (Vector Laboratories, Inc., Burlingame, Cali-
fornia) to yield a brownish reaction product. In the second
step, cell-specific antibodies were detected by an alkaline
phosphatase-labeled secondary antibody with Vector Red as
chromogen (Vector Laboratories). Endogenous alkaline
phosphatase was blocked by incubation with levamisole
(Dako).
Histologic analysis. Coronary artery specimens were ana-
lyzed by light microscopy, and atherosclerotic lesions were
defined according to the criteria set forth by the Committee
on Vascular Lesions of the Council on Arteriosclerosis of
the American Heart Association (3). Plaque areas were
stratified into (Ia) intima and (Ib) media adjacent to the
plaque, (II) shoulder region, (III) fibrous cap, and (IV) lipid
core as described by Jonasson et al. (17). In these areas
grading of ubiquitin immunoreactivity was performed by a
semiquantitative scale, defining absence of staining as Grade
0, weak intensity as Grade 1, intermediate intensity as
Grade 2, and strong intensity as Grade 3 (Fig. 1). From the
values obtained for these regions, mean ubiquitin staining
grades were calculated for the plaque area itself (regions II,
III, and IV), for the area adjacent to the plaque (regions Ia
and Ib), and for all regions of each lesion. Following
completion of analyses, performed by one observer, data
were stratified according to plaque grade for the entire
population and according to infarct-related and noninfarct-
related artery for one patient. The average coefficient of
correlation between five repetitive gradings of specimen
ubiquitin immunoreactivity was 0.812 0.032. The average
mean difference between five repetitive gradings of speci-
men ubiquitin immunoreactivity was 0.121  0.100.
Statistical analysis. Continuous data were expressed as
mean  SD, and categorical data were expressed as per-
centages. All comparisons of ubiquitin staining grades
between the regions of infarct-related and noninfarct-
related lesions of the same patient, as well as between the
different regions on lesion level, were made by signed-rank
Table 1. Study population
Number of Patients 25
Cardiovascular risk factors
Male gender 13 (52%)
Hyperlipidemia 7 (28%)
Systemic hypertension 14 (56%)
Smoking 7 (28%)
Obesity 9 (36%)
Family history 1 (4%)
Diabetes mellitus 8 (32%)
Cardiac history
Prior percutaneous coronary intervention 8 (32%)
Prior coronary artery bypass grafting 1 (4%)
Prior acute MI 15 (60%)
Congestive heart failure 10 (40%)
Clinical diagnosis
Acute MI 21 (84%)
Unstable angina pectoris 0 (0%)
Sudden cardiac death 4 (16%)
Pathologic diagnosis
MI 24 h 8 (32%)
MI 24 h 17 (68%)
Subendocardial MI 8 (32%)
Transmural MI 9 (36%)
Mixed MI 7 (28%)
Values are n (%).
MI  myocardial infarction.
Abbreviations and Acronyms
ACS  acute coronary syndrome
LDL  low density lipoprotein
MI  myocardial infarction
RT  room temperature
TdT  terminal deoxynucleotidyl transferase
TUNEL  terminal deoxynucleotidyl transferase
end labeling
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test. A p value 0.05 was considered statistically significant
for all analyses.
RESULTS
Study population. Demographic data for the study popu-
lation are presented in Table 1. Myocardial infarction to
death interval was 4.8  3.9 days, and death to autopsy
interval was 12.4  6.3 h. All patients had a history of
multivessel coronary artery disease.
Histology. The left anterior descending artery, the left
circumflex artery, and the right coronary artery was the
infarct-related artery in 13 (52%), 4 (16%), and 8 (32%) of
the cases, respectively. Among the infarct-related coronary
arteries, the Stary grade of the underlying lesion morphol-
ogy was Stary IV, Stary V, Stary VII, and Stary VIII in 2
(8%), 11 (44%), 9 (36%), and 3 (12%) of the cases,
respectively. A surface defect was observed in 18 cases (68%)
and isolated thrombus in 7 cases (32%). Among the
noninfarct-related coronary arteries, Stary grade V, VII, and
VIII were found in 7 (28%), 14 (56%), and 4 (16%) of the
cases, respectively.
Immunoreactivity. Ubiquitin immunoreactivity was sig-
nificantly higher in infarct-related than in noninfarct-
related lesions (1.4  0.5 vs. 1.1  0.6, p  0.03), which
was attributable mainly to greater staining within the plaque
area (2.3 0.6 vs. 1.5 0.7, p 0.001) rather than outside
the plaque area (0.5  0.7 vs. 0.8  0.7, p  0.09).
Specifically, ubiquitin immunoreactivity was higher in the
infarct-related lesions compared with the noninfarct-related
lesions in the shoulder region (2.1  0.9 vs. 1.0  0.9, p 
0.001) and in the region of the fibrous cap (2.2 0.9 vs. 1.0
 1.0, p  0.001), but not in the area around the lipid core
(2.6  0.7 vs. 2.3  0.9, p  0.3). No significant difference
in ubiquitin immunoreactivity between infarct-related and
noninfarct-related lesions was found in the intima (0.6 
0.8 vs. 1.0 0.9, p 0.1) or in the media (0.3 0.6 vs. 0.6
 0.7, p  0.2). Figure 2 gives a representative immuno-
histologic example.
Overall, ubiquitin immunoreactivity was higher around
the lipid core (2.5  0.8) compared with the shoulder
(1.5  1.1, p  0.001) and cap region (1.6  1.1, p 
0.001). In areas adjacent to the plaque, immunoreactivity
was higher in the intima than in the media (0.8  0.9 vs.
0.4  0.7, p  0.001) because of intense staining of cells at
the base of the neointima.
In less diseased (Stary II and Stary III) coronary artery
specimens from patients with noncardiac death, specific
ubiquitin staining was absent.
Tissue ubiquitin immunoreactivity was absent when the
slides were incubated with an unspecific isotype antibody
(rabbit IgG) or when recombinant ubiquitin was added to
the anti-ubiquitin antibody (ratio 2:1).
Co-localization. Immunostaining in serial sections indi-
cated co-localization of ubiquitin immunoreactivity with
neointimal cells and inflammatory cells in cap and shoulder
regions (Fig. 2C to 2F). Double immunostaining confirmed
co-localization of ubiquitin immunoreactivity with T cells
in areas of inflammatory cell infiltration (Fig. 3) and with
macrophages in lipid core regions (Fig. 4). Co-localization
of ubiquitin immunoreactivity with TUNEL-positive cells
was seen in lipid core as well as cap/shoulder regions (Fig.
5). In these regions, ubiquitin immunoreactivity co-
localized with p53 as well (Fig. 6). In the region adjacent to
the plaque, ubiquitin immunoreactivity co-localized with
neointimal cells and media smooth muscle cells.
DISCUSSION
The current study demonstrates high ubiquitin immunore-
activity in unstable coronary plaques in patients with ACS,
consistent with a potential role for the ubiquitin system in
Figure 1. Illustration of the immunostaining grades applied in the current
study. Original magnifications for all panels 37.5.
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Figure 2. Comparative illustration of ubiquitin immunostaining in the noninfarct-related coronary artery (A) versus the infarct-related coronary artery (B).
The area highlighted by the box in B is displayed at a higher magnification in C. Serial sections stained for smooth muscle alpha-actin (D) and T-cell
CD 3 (E) reveal co-localization of ubiquitin immunoreactivity with inflammatory cells and neointimal cells in the cap/shoulder region. Original
magnifications for A and B 15; for C to D 100.
Figure 3. Atherosclerotic plaque area characterized by infiltration of leukocytes, most of them revealing brown staining for ubiquitin (arrow in main panel)
and being identified as T cells by CD-3 immunostaining (A). Double immunofluorescence confirms co-localization of ubiquitin with T cells (round cells
with yellow fluorescence for ubiquitin in the center, surrounded by red fluorescence for CD-3, B). Original magnification for all panels 100.
progression and acute complication of coronary atheroscle-
rosis in humans.
Previous pathologic studies have identified a small fibrous
cap, formed by extracellular matrix components, and a large
necrotic core, formed by cellular and lipid debris, as the
characteristic morphology of unstable atherosclerotic plaque
(3,4). Indeed, most of the infarct-related lesions in the
current study exhibited this morphologic pattern and were
also characterized by infiltration of inflammatory cells (5).
Among them, T cells are regarded as a cell population of
quantitative and qualitative significance for the activity of
the inflammatory process. Notably, previous in-vitro studies
highlighted the involvement of the ubiquitin-proteasome
system in the metabolism of T cell antigen receptor sub-
units, affecting their assembly and function (18,19). These
experimental findings might explain the intense ubiquitin
immunoreactivity displayed by T cells in the current immu-
nohistologic study. Thus, ubiquitination can be localized to
T cells in regions of inflammatory cell infiltration of
atherosclerotic plaques, with the potential not only to affect
T cell function but overall inflammatory activity and plaque
stability.
Another area of strong ubiquitin immunoreactivity iden-
tified in the current study is the lipid core region, rich in
modified low density lipoprotein (LDL) and their degrada-
tion products (20). The important role for the ubiquitin
system in the degradation of oxidized proteins has been
known for years (21). Of note, it has been shown that
oxidative stress can, in fact, stimulate the ubiquitin system
in macrophages by inducing the expression of components
of its enzymatic machinery such as ubiquitin-binding pro-
teins (22). Furthermore, it has been demonstrated that
aggregated LDL induces the expression of the human
homologue of the bovine ubquitin-conjugating enzyme
E2-25K in human monocytes, which was associated with
polyubiquination of intracellular proteins (23). As p53 was
identified as one of the proteins undergoing ubiquitin-
dependent degradation, it was concluded that aggregated
LDL might contribute to foam cell formation by stimula-
tion of the ubiquitin-proteasome pathway and subsequent
degradation of pro-apoptotic proteins. Oxidized LDL
might have the same effect, although in high concentration
it can, in fact, inhibit the proteolytic activity of the protea-
some (24). Given unimpaired ubiquitination, this would
lead to the accumulation of ubiquitinated proteins and
increase in the half-life of substrates of the ubiquitin-
Figure 4. Lipid core area of an atherosclerotic plaque, in which co-localization of ubiquitin (brown) with macrophage CD 68 (red) is revealed by
double-immunostaining (arrow in main panel), including nuclear staining of a foam cell (arrowhead in inserted panel). Original magnification for both
panels 100.
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proteasome system such as p53 (24,25). Indeed in a previous
study on carotid atherectomy samples accumulation of p53
was demonstrated in all cell types of the plaque, but mainly
confined to macrophages and vascular smooth muscle cells
(26). Importantly, p53 accumulation localized to the same
compartments of the plaque as positive TUNEL staining,
mainly around the atheromatous gruel (26). In line with
these results, p53 immunoreactivity was found mainly in the
area of the lipid core and, to a lesser extent, in the
cap/shoulder region. In the present study, p53 immunore-
activity was found mainly with macrophages and, to a lesser
extent, with smooth muscle cells and T cells. Of further
note, p53 staining co-localized with ubiquitin immunore-
activity in the very same plaque area in which TUNEL-
positive cells were identified. Therefore, proteasome inhi-
bition with subsequent accumulation of substrates of the
ubiquitin-proteasome system has to be considered as an-
other explanation for extensive ubiquitin immunoreactivity
in human plaques in vivo. As exemplified for p53, these
accumulating substrates of the ubiquitin-proteasome system
can trigger the cellular death program, which eventually
leads to deoxyribonucleic acid fragmentation as visualized
Figure 5. Co-localization of ubiquitin (brown) with terminal deoxynucleotidyl transferase end labeling (TUNEL) positive cells (red) in lipid core area (A)
and cap/shoulder region (B). Double immunofluorescence (inserted panel) more clearly visualizes ubiquitin (yellow fluorescence) in the cytoplasm of cells,
which line cholesterol crystals of the lipid core and stain positive for TUNEL (red fluorescence). Original magnification for all panels 100.
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by positive TUNEL staining. The presence and significance
of apoptosis for progression and complication of atheroscle-
rotic plaques has been pointed out before (27–29). Thus,
given previous and current study findings, the ubiquitin
system can, potentially, be involved in cell survival as well as
in cell death in atherosclerosis, with significance for the
course of the overall disease process.
In areas adjacent to the plaque, ubiquitin immunoreac-
tivity was confined to media smooth muscle and neointimal
cells, whereas immunoreactivity was more pronounced in
the neointimal cells. Previously, in situ hybridization of a
polyubiquitin riboprobe to sections of diseased human
coronary arteries demonstrated higher expression of poly-
ubiquitin in media smooth muscle cells than in neointimal
cells (30). An immunohistochemical study on the expression
of ubiquitin in normal and injured rat aorta, however,
demonstrated intense cellular ubiquitin staining in neointi-
mal regions, and a role for the ubiquitin system in prolifer-
ation cell turnover was suggested on the basis of these
findings (31). Additionally, enhanced ubiquitin immunore-
activity in these regions might be due to local hypoxia
secondary to impairment of oxygen diffusion capacity and
even increase in oxygen demand (32,33). Thus, the current
study indicates a role for the ubiquitin system in the
Figure 6. Lipid core region (A) and cap region (B) revealing co-localization of ubiquitin (brown) with p53 (red) in macrophages (inserted panel in A, and
lower inserted panel in B) and vascular smooth muscle cells (upper inserted panel in B). Original magnification for main panels and inserted panels 75
and 150, respectively.
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metabolic activity not only of media smooth muscle cells,
but also of neointimal cells in the atherosclerotic arterial
wall.
Overall, ubiquitin immunoreactivity in advanced athero-
sclerotic lesions was higher in infarct-related coronary
arteries than in noninfarct-related coronary arteries of the
same patient in this study, which was attributable to a
higher immunoreactivity in the cap and shoulder regions in
infarct-related arteries. Previous reports have outlined a
pathomechanistic role for inflammation as well as apoptosis
in the process of plaque destabilization (1,2,5,28,29). Of
note, both these processes have been associated with alter-
ations in the ubiquitin-proteasome system, including in-
creased ubiquitin expression on tissue level (25,34–36). In
line with these previous reports, ubiquitin immunoreactivity
co-localized with both inflammatory cells and apoptotic
cells in cap and shoulder regions in the current study,
indicating an involvement of the ubiquitin proteasome
system in inflammation and apoptosis with potential impact
upon plaque stability. Of note, the cellular target proteins of
the ubiquitin-proteasome system in these different biologic
processes and cells can differ to various extent. Thus, in
nonuniform manner the ubiquitin-proteasome system
might be involved in the progression and complication of
the atherosclerotic plaque.
Study limitations. One limitation of the current study is its
retrospective and descriptive character. However, the patho-
histologic approach allowed localization and semiquantita-
tive evaluation of the expression of ubiquitin in a well-
defined series of lesions of both infarct-related and
noninfarct-related coronary arteries from the same patients
in whom the diagnosis of AMI was confirmed by autopsy.
Although this study cannot give further mechanistic insight
and cannot prove a causative role for the ubiquitin system in
plaque instability, it demonstrates the topographics expres-
sion of ubiquitin within advanced human atherosclerotic
plaques and shows overall higher immunoreactivity of le-
sions of infarct-related arteries. It has to be noted that
plaque composition differed between the two groups, with a
higher prevalence of fibrotic and calcified lesions in the
group of noninfarct-related coronary arteries; however, this
is unavoidable due to the design of the current study.
Further studies are warranted to define the functional
significance of the enhanced ubiquitin expression in ad-
vanced coronary artery lesion associated with acute coronary
syndromes. Furthermore, prospective clinical studies
would allow sampling of fresh tissue and the application of
quantitative methods of the determination of tissue protein
expression.
Conclusions. The current study demonstrates enhanced
ubiquitin immunoreactivity in unstable, infarct-related
plaques, predominantly in plaque regions of tissue degrada-
tion. In areas adjacent to the plaque, ubiquitin immunore-
activity was enhanced at the base of the neointima. Based on
these findings, the current study suggests a role for the
ubiquitin system in progression and complication of coro-
nary atherosclerotic plaques in humans.
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